A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD

Launched by SKYLINE THERAPEUTICS · Apr 3, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a treatment called SKG0106 for patients with a condition known as neovascular (wet) age-related macular degeneration (nAMD), which affects vision. The study is designed to follow patients who have already received this treatment in earlier studies to see how well it works and if it is safe over a long period, up to five years after their last injection.

To be part of this study, participants need to have previously been enrolled in the related SKG0106 studies and received the injection. They also need to willingly agree to participate by signing a consent form. Throughout the study, patients will have regular check-ups to monitor their health and the effectiveness of the treatment. This is a great opportunity for those who qualify to contribute to important research that could improve care for others with similar vision issues.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Subjects who only meet all of the following criteria are eligible for this study:
• • nAMD subjects who have been enrolled in the SKG0106-related study and received SKG0106 injection;
• • Subjects who voluntarily sign an informed consent form (ICF) and comply with the protocol to complete the study
• Exclusion Criteria:
• • Subjects who are judged by the investigator unsuitable for this study